Enochian gets license for inhaled treatment tech

By The Science Advisory Board staff writers

June 21, 2021 -- Enochian BioSciences has acquired a license for technology that can potentially treat and prevent all variants of the coronavirus as well as influenza.

Developed by Dr. Serhat Gumrukçu, PhD, director of Seraph Research Institute, the inhaled drug tricks the viruses to trigger the cells they infect to commit suicide instead of becoming virus-making factories. Delivered via a nanoparticle, the drug either rapidly treats an infection or waits for a cell to become infected before attacking it. It's possible a single inhalation of the drug could both treat and protect against infection for relatively long periods of time, according to Enochian.

The firm is requesting a preinvestigational new drug meeting with the U.S. Food and Drug Administration (FDA) soon.

Financial details of the license were not disclosed.


Copyright © 2021 scienceboard.net


Conferences
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Cell & Gene Meeting on the Mesa
October 11-13
Carlsbad, California United States
IDWeek 2022
October 19-23
District of Columbia United States
American Society of Human Genetics Annual Meeting
October 25-29
Los Angeles, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter